Revelation Biosciences (NASDAQ: REVB) furnishes new corporate presentation
Rhea-AI Filing Summary
Revelation Biosciences, Inc. furnished an updated corporate presentation, dated June 1, 2026, and made it available to the public on its website. The presentation is attached as Exhibit 99.1 to this report under Item 8.01 Other Information and is incorporated by reference.
The company clarifies that the materials in Item 8.01 and Exhibit 99.1 are being furnished, not filed, so they are not subject to certain Exchange Act liabilities and are only incorporated into other filings if specifically referenced. Item 9.01 lists Exhibit 99.1 and an Inline XBRL cover page file as Exhibit 104.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Terms
corporate presentation financial
Emerging growth company regulatory
Inline XBRL technical
Item 8.01 Other Information regulatory
Exhibit 99.1 regulatory
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
|||
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Information.
On June 1, 2026, Revelation Biosciences, Inc. (the “Company”) prepared and released an updated corporate presentation made available to the public. The corporate presentation can be found on the Company’s website. A copy of the presentation is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 8.01 and in Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
||
|
|
|
Exhibit No. |
|
Description |
99.1 |
|
Corporate Presentation, dated June 1, 2026 |
104 |
|
Cover Page Interactive Data File (embedded with the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
REVELATION BIOSCIENCES, INC. |
|
|
|
Date: June 1, 2026 |
By: |
/s/ Chester S. Zygmont, III |
|
|
Chester S. Zygmont, III |
Exhibit 99.1
